Sign Up to like & get recommendations! 0
Published in 2021 at "Journal of Neurology"
DOI: 10.1007/s00415-021-10519-4
Abstract: Subjective complaints of cognitive deficits are not necessarily consistent with objective evidence of cognitive impairment in Parkinson’s disease (PD). Here we examined the factors associated with the objective-subjective cognitive discrepancy. We consecutively enrolled 90 non-demented… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Neurological Sciences"
DOI: 10.1007/s10072-021-05271-6
Abstract: This study aims to investigate the extent to which sleep duration and efficiency are associated with plasma amyloid-β (Aβ) levels in non-demented older people. This study is a cross-sectional analysis of 305 non-demented older people.… read more here.
Sign Up to like & get recommendations! 1
Published in 2020 at "Archives of Clinical Neuropsychology"
DOI: 10.1093/arclin/acaa068.04
Abstract: Apolipoprotein (ApoE)-e4 is well established as a genetic risk factor for Alzheimer’s disease (AD) as well as a predictor for the rate of cognitive decline in AD. Among older adults without dementia, some research has… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Brain"
DOI: 10.1093/brain/awac297
Abstract: Abstract Phosphorylated Tau181 (pTau181) in CSF and recently in plasma has been associated with Alzheimer’s disease. In the absence of amyloidopathy, individuals with increased total Tau levels and/or temporal lobe atrophy experience no or only… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Dementia and Geriatric Cognitive Disorders"
DOI: 10.1159/000501366
Abstract: Background: An increasing number of studies suggest the importance of prospective memory (ProM) due to its functional relevance and sensitivity to neuropathology. However, its relevant neural substrates have not been sufficiently explored. Objectives: The present… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Translational Neurodegeneration"
DOI: 10.1186/s40035-018-0120-1
Abstract: BackgroundCognitive impairment is one of the non-motor symptoms in Parkinson’s disease (PD). In the present study, we aim to examine the cognitive function of non-demented Parkinson’s disease patients and compare the results between male and… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Translational Neurodegeneration"
DOI: 10.1186/s40035-020-00222-1
Abstract: Background Accumulating reports have suggested that α-synuclein is involved in the pathogenesis of Alzheimer’s disease (AD). As the cerebrospinal fluid (CSF) α-synuclein has been suggested as a potential biomarker of AD, this study was set… read more here.
Sign Up to like & get recommendations! 0
Published in 2022 at "Journal of integrative neuroscience"
DOI: 10.31083/j.jin2106168
Abstract: BACKGROUND Sleep disturbance is common in the elderly. The effect of sleep duration on cognitive function in the non-demented older adults with high school or above education needs to be clarified. Here, we conducted a… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of Alzheimer's Disease"
DOI: 10.3233/jad-210607
Abstract: Alzheimer’s disease (AD) is the most common form of dementia and typically characterized by the accumulation of amyloid-β plaques and tau tangles. Intriguingly, there also exists a group of elderly which do not develop dementia… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Frontiers in Genetics"
DOI: 10.3389/fgene.2021.642327
Abstract: Objectives Myocyte Enhancer Factor 2C (MEF2C) is identified as a candidate gene contributing to the risk of developing Alzheimer’s disease. However, little is known about whether MEF2C plays a role in specific aspects of cognition… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "Frontiers in Aging Neuroscience"
DOI: 10.3389/fnagi.2023.1121500
Abstract: Introduction Alzheimer’s disease (AD) is indicated by a decrease in amyloid beta 42 (Aβ42) level or the Aβ42/Aβ40 ratio, and by increased levels of Tau with phosphorylated threonine at position 181 (pTau181) in cerebrospinal fluid… read more here.